Loading...
•
Jun 30, 2022
Dynavax Q2 2022 Earnings Report
Reported second quarter financial results with a 386% increase in total revenue compared to Q2 2021.
Key Takeaways
Dynavax reported strong second-quarter results, driven by significant growth in both HEPLISAV-B and CpG 1018 adjuvant revenues. The company is on track for another profitable year and is well-capitalized to invest in programs that drive revenue growth and advance its clinical pipeline.
Total revenue for Q2 2022 reached $256.5 million, a 386% increase compared to $52.8 million in Q2 2021.
HEPLISAV-B vaccine net product revenue was $32.7 million, up 139% from $13.7 million in Q2 2021.
CpG 1018 adjuvant net product revenue was $222.6 million, up 471% from $39.0 million in Q2 2021.
The company anticipates adolescent data from the Tdap vaccine program trial in the fourth quarter of 2022 and topline data from the Shingles vaccine program also in the fourth quarter of 2022.
Revenue by Segment
Forward Guidance
Dynavax anticipates 2022 revenues, operating expenses, and other costs to be in the ranges shown below, updated from the Company’s previous financial guidance provided on May 5, 2022:
Positive Outlook
- Full-year CpG 1018 adjuvant net product revenues of between $550 million and $600 million
- Associated gross margin anticipated to be approximately 60%
Challenges Ahead
- Research and development expenses to be between approximately $50-$60 million
- Selling, general and administrative expenses to be between approximately $130-$140 million
- Interest expense of approximately $7 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...